Skip to main content
. 2020 Oct 27;4(20):5311–5321. doi: 10.1182/bloodadvances.2020003110

Table 1.

Baseline characteristics (N = 208)

Number of patients
Recipient age, median (min, max), y 52 (19, 75)
Donor age, median (min, max), y 38 (15, 73)
Male 113 (54)
Race
 White 123 (59)
 Black 80 (39)
 Asian 5 (2)
Recipient CMV status
 Positive 161 (77)
 Negative 47 (23)
Disease type
 AML 71 (34)
 NHL/HD/CLL 51 (25)
 MDS/MPN/CML 42 (20)
 ALL 36 (17)
 MM 5 (3)
 AL 3 (1)
DRI
 Low 30 (14)
 Intermediate 100 (48)
 High 68 (33)
 Very high 9 (4)
 N/A 1 (1)
HCT-specific comorbidity index
 0-2 113 (54)
 ≥3 95 (46)
Stem cell source
 PBSC 137 (66)
 BM 71 (34)
Conditioning intensity
 NMA 122 (59)
 MA 86 (41)
Donor-recipient relationship
 Child 99 (47)
 Sibling/half sibling 79 (38)
 Parent 29 (14)
 Niece/nephew 1 (1)
Year of transplant
 2005-2010 49 (24)
 2011-2013 63 (30)
 2014-2016 96 (46)
Number of survivors 105
Survivor follow-up, median (min, max), mo 65.4 (34.3, 157.2)

Values are presented as the number (percentage) of patients unless otherwise indicated.

AL, acute leukemia unspecified; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; MM, multiple myeloma; N/A, not available; NHL, non-Hodgkin lymphoma.